VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902

Ontario Industry Updates
Written By Maura Campbell

VBI Vaccines Inc., a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, announced the initiation of enrollment of its Phase 1/2 clinical study of VBI-2902, the Company’s monovalent enveloped virus-like particle (eVLP) COVID-19 vaccine candidate.

Maura Campbell
Previous

KA Imaging Appoints World-Renowned Radiologist, Dr. Philip Templeton, as Chief Medical Officer
Next

OBIO Announces new Chair of the Board of Directors, Dr. Maura Campbell